The Patent Finder

Terms ending in 2041

AbbVie Inc.

Every in-force patent on AbbVie Inc.'s record whose computed term ends in 2041, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 12,365,729Anti-Hemojuvelin (HJV) Antibodies for Treating Myelofibrosis
In force
 · High confidence
AbbVie Deutschland GmbH & Co. KGIn forceHigh confidence
US 12,497,452Anti-Hemojuvelin (HJV) Antibodies for Treating Myelofibrosis
In force
 · High confidence
AbbVie Deutschland GmbH & Co. KGIn forceHigh confidence
US D1,133,906Container Cap
In force
 · High confidence
AbbVie Inc.In forceHigh confidence
US 11,639,390ANTI-ALPHA-4-BETA-7 Antibodies
In force
 · High confidence
AbbVie Inc.In forceHigh confidence
US 11,897,672Sleeve Containers for Packaging Medicinal Products
In force
 · High confidence
AbbVie Inc.In forceHigh confidence
US D1,154,095Carrying Pack for Medical Device
In force
 · High confidence
AbbVie Inc.In forceHigh confidence
6 of 6 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited